PRJNA543001
Exome and Rnaseq of murine tumors treated with  combination of GAd vaccine and anti-PD1
Neoantigen cancer vaccines are a promising approach to enhance the efficacy of checkpoint blockade therapy (CPB) by increasing the breadth and potency of nAg specific T cells. Non-human Great Ape Adenoviruses (GAd) represent a safe and powerful genetic vaccine platform in humans. Here, we explored the efficacy of GAd encoding multiple neoantigens in combination with CPB on mouse tumors. Whole exome and RNA Sequencing were performed on CT26 and MC38 tumors to identify somatic mutations and predict potential immunogenic epitopes to be encoded in GAd vectors. Combination of GAd and anti-PD1 showed synergistic anti-tumor activity. DNA and RNA Sequencing were performed on tumors from responders and non-responder mice to identify mechanisms associated with therapeutic efficacy of nAgs vaccination.